The Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmacuticals’ zanidatamab-hrii (Ziihera) a bispecific HER2-directed antibody.  It is approved for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.  The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!